FOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer.

ABSTRACT:

Background

FOXD3 is aberrantly regulated in several tumors, but its underlying mechanisms in ovarian cancer (OC) remains largely unknown. The present study aimed to explore the role and associated mechanisms of FOXD3 in OC.

Methods

Microarray data from GEO was used to analyze differential CpG sites and differentially methylated regions (DMR) in tumor tissues and Illumina 450 genome-wide methylation data was employed. The FOXD3 expression level was determined through qRT-PCR and western blot analysis. Wound healing test, colony formation and flow cytometry assay were utilized to analyze cell migration, proliferation abilities, cell cycle and cell apoptosis, respectively. Finally, the effect of FOXD3 on tumor growth was investigated through in vivo

SUBMITTER: Luo GF 

PROVIDER: S-EPMC6394078 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature